Effects of Antiviral Therapy on HBV Reactivation

• Status: Completed
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Hepatitis B virus (HBV) reactivation happens after liver resection for HBV-related hepatocellular carcinoma (HCC) patients, particularly for those with positive serum HBV-DNA . The incidence rate and risk factors of HBV reactivation after hepatectomy for serum HBV-DNA negative HBV-related HCC are unclear.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Guangxi Medical University
• Treatments: Antiviral Agents; Entecavir

Criteria

Inclusion Criteria:

• underwent initial hepatectomy;

• preoperative serum HBsAg positive

• serum HBV DNA negative

• serum ALT in normal range

• Child-Pugh A liver function

• HCC was confirmed by histopathology

• patients in the treated group received Entecavir (ENT) while patients in the control group did not receive any antiviral therapy.

Exclusion Criteria:

• underwent preoperative TACE or other anti-tumor treatments

• underwent preoperative antiviral treatment for nearly a year

• with autoimmune disease, other organ malignant tumor, or other severe disease.